Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:
“Excited to be a speaker at the 4th Annual Driver Alterations and Targeted Therapies in Advanced NSCLC in Chandigarh, India!
I’ll be debating optimal sequencing of therapies for EGFR-mutated NSCLC, diving into the role of upfront monotherapy vs. combination strategies and what it means for patient outcomes.
Looking forward to insightful discussions and learning from colleagues advancing lung cancer care!”
More posts featuring Aakash Desai.
